Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.

@article{Lizarzaburu2012DiscoveryAO,
  title={Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.},
  author={M. Lizarzaburu and S. Turcotte and X. Du and Jason Duquette and Angela Fu and Jonathan B. Houze and L. Li and J. Liu and M. Murakoshi and K. Oda and R. Okuyama and F. Nara and J. Reagan and M. Yu and J. Medina},
  journal={Bioorganic & medicinal chemistry letters},
  year={2012},
  volume={22 18},
  pages={
          5942-7
        }
}
The discovery and initial optimization of a series of phenylalanine based agonists for GPR142 is described. The structure-activity-relationship around the major areas of the molecule was explored to give agonists 90 times more potent than the initial HTS hit in a human GPR142 inositol phosphate accumulation assay. Removal of CYP inhibition by exploration of the pyridine A-ring is also described. 
24 Citations
Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.
  • 10
Discovery and pharmacological effects of a novel GPR142 antagonist
  • 6
...
1
2
3
...

References

SHOWING 1-5 OF 5 REFERENCES
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.
  • 253
  • PDF
High throughput screening for orphan and liganded GPCRs.
  • 33